“Luminal B” is a label pathologists use for a pattern of test results: a breast cancer that has hormone receptors (estrogen receptors, progesterone receptors, or both) and shows signs of growing faster than its close relative, luminal A. Depending on the definition a team uses, the HER2 result may be not high, or in some cases high. It is one of the standard ways of grouping breast cancers by their biology, and it sits alongside — not instead of — the other words on your pathology report, such as where the cancer began, its grade, and its stage.
Key Takeaways
- “Luminal B” describes a pattern: hormone receptors present, with signs of growth that are generally faster than in luminal A.
- The HER2 result may be not high, or — in some definitions of the pattern — high. Teams draw the luminal B boundary slightly differently.
- The pattern is read from laboratory tests on the biopsy tissue: hormone receptors, HER2, and a growth marker often called Ki-67.
- The line between luminal A and luminal B is the softest boundary in this family, because it is drawn from growth signs rather than from a clear yes-or-no test.
- Because the cancer has hormone receptors, treatments that act on hormones are among the approaches a team may consider. If HER2 is high, HER2-directed approaches may be considered too.
- Individual cases differ. The label is one layer of your report — stage, grade, lymph node findings, and your overall health matter just as much.
What the Name Means
The ducts and lobules of the breast are lined with cells, and the layer facing the inside of the duct is called the luminal layer. When researchers first grouped breast cancers by which genes they switch on, some cancers looked most like those lining cells, and those groups were named “luminal.” The luminal family has two commonly used members: luminal A and luminal B.
In everyday practice, the label is usually applied from the standard laboratory results rather than from gene testing. A cancer is generally described as luminal B when hormone receptors are present and the growth signs point to a faster-growing cancer than the luminal A pattern. Our pillar guide, Types of Breast Cancer Compared, shows how this grouping fits with the other ways a cancer is described — by where it began, by its type, and by its stage.
The grouping matters because cancers with different biology behave differently and respond to different kinds of treatment. It helps care teams communicate, plan, and compare cases in research. But a group label is a summary, not a verdict: two cancers can share the luminal B label and still differ in size, stage, and how they are managed.
How Luminal B Differs From Luminal A
Luminal A and luminal B are neighbours, and the differences between them are matters of degree rather than completely different diseases. Three differences come up most often:
- Growth signs. In luminal B, more of the cancer cells appear to be actively dividing. The growth marker on the report sits at the higher end, and the grade is often higher too.
- Progesterone receptor level. Both patterns have hormone receptors, but in luminal B the progesterone receptor result is sometimes lower or weaker.
- HER2. In luminal A, HER2 is not high. In luminal B, some definitions include cancers with high HER2 when hormone receptors are present, while others use the name only for faster-growing cancers whose HER2 is not high.
The table below sets out the commonly used biology groupings in general terms. It describes test-result patterns only; it is not a ranking of how serious a cancer is, because that depends on the full picture in each individual case.
| Pattern | Hormone receptors | HER2 | Growth pattern, in general |
|---|---|---|---|
| Luminal A | Present | Not high | Generally slower-growing |
| Luminal B | Present (progesterone receptor sometimes lower) | Not high, or high in some definitions | Generally faster-growing than luminal A |
| HER2-positive (hormone receptor-negative) | Absent | High | Varies |
| Triple-negative | Absent | Not high | Varies |
Because the boundary is drawn from growth signs, a cancer near the line may be described slightly differently by different teams, without anyone being wrong — the underlying test results are the same, and it is those results, more than the label, that planning is built on. Our companion article, Luminal A Breast Cancer Explained, sets out the other side of this comparison in the same plain terms.
How the Pattern Is Found on Your Report
Three kinds of laboratory result feed into the luminal B description, and each may appear as its own line on your pathology report:
- Hormone receptors. Tests called immunohistochemistry (IHC) check whether the cancer cells carry receptors for estrogen (ER) and progesterone (PR) — small structures that respond to those hormones. A result of positive means the receptors are present, and the hormones may be among the signals helping the cancer grow.
- HER2. HER2 is a protein on the surface of breast cells that also plays a part in growth. In a luminal B pattern, the HER2 result may be in the not-high range or, under some definitions, high. Our article on HER2-low breast cancer explains the not-high vocabulary and how it differs from HER2-positive.
- A growth marker. Reports often include a marker called Ki-67, which gives the laboratory a general sense of how many of the cancer cells are actively dividing. In a luminal B pattern this measure is generally at the higher end. Laboratories do not all draw the lower/higher line in exactly the same place, so treat the label as your team’s reading of the whole set of results rather than a single score.
Grade plays a supporting part too: grade describes how different the cells look from normal cells and how quickly they appear to be growing, and luminal B cancers are often of a higher grade than luminal A. If your report does not use the words “luminal B” at all, that is common — many reports simply list the receptor results, and the grouping is something your team may refer to in discussion rather than in writing.
What It Can Mean for Treatment Planning
The practical importance of the luminal B pattern starts with the hormone receptors. Because the cancer cells carry them, approaches that block the hormones or lower their levels are among the tools a care team may consider. Our comparison of hormone receptor-positive and triple-negative breast cancer explains why the presence or absence of receptors changes the range of approaches so much. If HER2 is high in your case, HER2-directed approaches may enter the planning as well.
Whether other treatments, such as chemotherapy, are recommended is a separate and individual judgement. It depends on the cancer’s stage and size, whether lymph nodes are involved, the grade, your age and overall health, and sometimes additional tests your team may discuss with you. This article names no specific medicines and recommends no particular plan, because the right combination and timing belong with your own doctor and care team, who can read the label alongside everything else they know about your case.
A faster-growing pattern is information, not a prediction about any one person. It does not tell you how your own cancer will behave, and it is not a reason to skip follow-up or monitoring. If anything about the plan seems inconsistent with what you have read about luminal B, ask your team to talk you through how they weighed the pieces in your case.
Questions to Ask Your Doctor
- Can you walk me through the results that place my cancer in the luminal B group?
- What were my estrogen receptor, progesterone receptor, HER2, and Ki-67 results?
- Is my HER2 result in the not-high range, or is it high?
- What were my grade and stage, and how do they fit with this pattern?
- Which parts of my treatment plan follow from the hormone receptors being present?
- How did the team decide whether chemotherapy would or would not help in my case?
- What follow-up and monitoring will I have, and what should I watch for between visits?
Frequently Asked Questions
Is luminal B a separate type of breast cancer?
It is a grouping based on biology — the receptor and growth-marker results — rather than a description of where the cancer began. A luminal B cancer can be ductal, lobular, or another type, and the descriptions apply at the same time. Think of it as one layer of your report, not a replacement for the others.
Is luminal B more serious than luminal A?
The pattern is generally associated with faster growth, but no single label decides how serious a cancer is. Stage — how large it is and whether it has spread — grade, and how it responds to treatment all matter at least as much. Your care team can explain how the pieces fit together in your own case.
Why might two hospitals describe the same cancer differently?
The luminal A/B line is drawn from growth-marker results, and laboratories do not all set that line in the same place. A cancer close to the boundary may be given either label while the underlying results stay identical. This is one reason the individual results on your report matter more than the group name alone.
Why does my report not say “luminal B” anywhere?
Many pathology reports list the individual results — ER, PR, HER2, Ki-67 — without applying the group label at all. The grouping is often used in discussion, in research, and in some teams’ planning language. If the individual results match the pattern described here, your team can confirm whether they would use the term for your cancer.
Where can I read more?
Our pillar guide compares the main types and patterns side by side. General background on receptor testing and breast cancer biology is also published by the American Cancer Society (cancer.org) and the National Cancer Institute (cancer.gov). Your own report, explained by your own team, is the source that matters most.
Related Articles
- Types of Breast Cancer Compared: A Complete Guide
- Luminal A Breast Cancer Explained
- HER2-Low Breast Cancer Explained in Plain English
- Hormone Receptor-Positive vs Triple-Negative Breast Cancer
This article is for general educational purposes only and is not medical, legal, or financial advice. It does not replace professional care. Talk to your doctor or care team about your own situation. If you think you may have a medical emergency, call 911.